(HOLX) Hologic - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 16.897m USD | Total Return: 23.2% in 12m

Stock Diagnostics, Imaging, Surgical, Skeletal
Total Rating 55
Risk 95
Buy Signal -0.14
Medical Instruments & Supplies -2.1
Health Care Equipment -3.7
Market Cap: 16,897m
Avg Trading Vol: 206M USD
ATR: 0.31%
Peers RS (IBD): 75.6
Risk 5d forecast
Volatility3.16%
Rel. Tail Risk-7.07%
Reward TTM
Sharpe Ratio0.76
Alpha14.20
Character TTM
Beta0.341
Beta Downside0.256
Drawdowns 3y
Max DD39.85%
CAGR/Max DD-0.06
EPS (Earnings per Share) EPS (Earnings per Share) of HOLX over the last years for every Quarter: "2021-03": 2.59, "2021-06": 1.33, "2021-09": 1.61, "2021-12": 2.17, "2022-03": 2.07, "2022-06": 0.95, "2022-09": 0.82, "2022-12": 1.07, "2023-03": 1.06, "2023-06": 0.93, "2023-09": 0.89, "2023-12": 0.98, "2024-03": 1.03, "2024-06": 1.06, "2024-09": 1.01, "2024-12": 1.03, "2025-03": 1.03, "2025-06": 1.08, "2025-09": 1.13, "2025-12": 1.04,
EPS CAGR: -16.77%
EPS Trend: -16.3%
Last SUE: -3.25
Qual. Beats: 0
Revenue Revenue of HOLX over the last years for every Quarter: 2021-03: 1537.6, 2021-06: 1168.3, 2021-09: 1316.6, 2021-12: 1471.1, 2022-03: 1435.7, 2022-06: 1002.7, 2022-09: 953.2, 2022-12: 1074.2, 2023-03: 1026.5, 2023-06: 984.4, 2023-09: 945.3, 2023-12: 1013.1, 2024-03: 1017.8, 2024-06: 1011.4, 2024-09: 988, 2024-12: 1021.8, 2025-03: 1005.3, 2025-06: 1023.8, 2025-09: 1049.5, 2025-12: 1047.8,
Rev. CAGR: -8.06%
Rev. Trend: -27.6%
Last SUE: -3.01
Qual. Beats: 0
Description: HOLX Hologic

Hologic, Inc. (NASDAQ: HOLX) develops, manufactures, and supplies a broad portfolio of womens health solutions-including diagnostics, medical imaging, and surgical products-across four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its offerings range from Aptima molecular assays for infectious diseases and SARS-CoV-2 to 3D digital mammography systems and minimally invasive uterine-fibroid devices.

In its most recent fiscal year (2025), Hologic reported revenue of $5.2 billion, a 7% year-over-year increase driven by strong growth in the Breast Health segment (+9%) and sustained demand for COVID-19 and HPV testing in Diagnostics. The company posted an adjusted EBITDA margin of 22%, reflecting operational efficiencies from its direct-sales model. Industry trends such as the expanding women’s-health market-projected to grow at a 6% CAGR through 2030-and the shift toward outpatient surgical procedures continue to underpin Hologic’s growth outlook.

For deeper insights, you might explore ValueRay’s analysis of HOLX.

Headlines to Watch Out For
  • Diagnostic assay sales for infectious diseases drive revenue
  • Breast health product demand impacts financial performance
  • GYN surgical product adoption influences growth
  • Skeletal health system sales contribute to revenue
  • Regulatory approvals for new products affect market access
Piotroski VR‑10 (Strict) 6.5
Net Income: 543.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.89 > 1.0
NWC/Revenue: 70.09% < 20% (prev 61.68%; Δ 8.41% < -1%)
CFO/TA 0.12 > 3% & CFO 1.10b > Net Income 543.9m
Net Debt (352.3m) to EBITDA (1.01b): 0.35 < 3
Current Ratio: 4.04 > 1.5 & < 3
Outstanding Shares: last quarter (225.9m) vs 12m ago -2.68% < -2%
Gross Margin: 52.82% > 18% (prev 0.56%; Δ 5.23k% > 0.5%)
Asset Turnover: 46.08% > 50% (prev 46.27%; Δ -0.19% > 0%)
Interest Coverage Ratio: 8.00 > 6 (EBITDA TTM 1.01b / Interest Expense TTM 95.2m)
Altman Z'' 4.85
A: 0.32 (Total Current Assets 3.84b - Total Current Liabilities 951.3m) / Total Assets 9.18b
B: 0.39 (Retained Earnings 3.59b / Total Assets 9.18b)
C: 0.09 (EBIT TTM 761.8m / Avg Total Assets 8.95b)
D: 0.89 (Book Value of Equity 3.50b / Total Liabilities 3.94b)
Altman-Z'' Score: 4.85 = AA
Beneish M -3.12
DSRI: 0.91 (Receivables 584.2m/631.4m, Revenue 4.13b/4.04b)
GMI: 1.06 (GM 52.82% / 55.98%)
AQI: 0.97 (AQ_t 0.52 / AQ_t-1 0.54)
SGI: 1.02 (Revenue 4.13b / 4.04b)
TATA: -0.06 (NI 543.9m - CFO 1.10b) / TA 9.18b)
Beneish M-Score: -3.12 (Cap -4..+1) = AA
What is the price of HOLX shares? As of April 02, 2026, the stock is trading at USD 75.59 with a total of 2,472,698 shares traded.
Over the past week, the price has changed by +0.11%, over one month by +0.20%, over three months by +1.39% and over the past year by +23.17%.
Is HOLX a buy, sell or hold? Hologic has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold HOLX.
  • StrongBuy: 3
  • Buy: 3
  • Hold: 14
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the HOLX price?
Wallstreet Target Price 76.7 1.4%
Analysts Target Price 76.7 1.4%
HOLX Fundamental Data Overview as of 28 March 2026
P/E Trailing = 31.4066
P/E Forward = 16.6945
P/S = 4.0949
P/B = 3.2096
P/EG = 1.6608
Revenue TTM = 4.13b USD
EBIT TTM = 761.8m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 12.8m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 352.3m USD (from netDebt column, last quarter)
Enterprise Value = 17.05b USD (16.90b + Debt 2.52b - CCE 2.36b)
Interest Coverage Ratio = 8.00 (Ebit TTM 761.8m / Interest Expense TTM 95.2m)
EV/FCF = 17.06x (Enterprise Value 17.05b / FCF TTM 999.6m)
FCF Yield = 5.86% (FCF TTM 999.6m / Enterprise Value 17.05b)
FCF Margin = 24.22% (FCF TTM 999.6m / Revenue TTM 4.13b)
Net Margin = 13.18% (Net Income TTM 543.9m / Revenue TTM 4.13b)
Gross Margin = 52.82% ((Revenue TTM 4.13b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 55.96% (prev 60.90%)
Tobins Q-Ratio = 1.86 (Enterprise Value 17.05b / Total Assets 9.18b)
Interest Expense / Debt = 1.10% (Interest Expense 27.6m / Debt 2.52b)
Taxrate = 22.03% (50.6m / 229.7m)
NOPAT = 594.0m (EBIT 761.8m * (1 - 22.03%))
Current Ratio = 4.04 (Total Current Assets 3.84b / Total Current Liabilities 951.3m)
Debt / Equity = 0.48 (Debt 2.52b / totalStockholderEquity, last quarter 5.25b)
Debt / EBITDA = 0.35 (Net Debt 352.3m / EBITDA 1.01b)
Debt / FCF = 0.35 (Net Debt 352.3m / FCF TTM 999.6m)
Total Stockholder Equity = 4.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 543.9m / Total Assets 9.18b)
RoE = 11.01% (Net Income TTM 543.9m / Total Stockholder Equity 4.94b)
RoCE = 10.24% (EBIT 761.8m / Capital Employed (Equity 4.94b + L.T.Debt 2.50b))
RoIC = 7.97% (NOPAT 594.0m / Invested Capital 7.45b)
WACC = 6.36% (E(16.90b)/V(19.42b) * Re(7.18%) + D(2.52b)/V(19.42b) * Rd(1.10%) * (1-Tc(0.22)))
Discount Rate = 7.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -3.03%
[DCF] Terminal Value 83.98% ; FCFF base≈1.05b ; Y1≈968.3m ; Y5≈880.4m
[DCF] Fair Price = 104.2 (EV 23.62b - Net Debt 352.3m = Equity 23.27b / Shares 223.2m; r=6.36% [WACC]; 5y FCF grow -9.37% → 3.0% )
EPS Correlation: -16.25 | EPS CAGR: -16.77% | SUE: -3.25 | # QB: 0
Revenue Correlation: -27.58 | Revenue CAGR: -8.06% | SUE: -3.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.11 | Chg7d=+0.000 | Chg30d=-0.009 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-09-30): EPS=4.43 | Chg7d=+0.012 | Chg30d=+0.012 | Revisions Net=-8 | Growth EPS=+4.0% | Growth Revenue=+3.3%
EPS next Year (2027-09-30): EPS=3.78 | Chg7d=+0.000 | Chg30d=-0.230 | Revisions Net=-5 | Growth EPS=+15.4% | Growth Revenue=+5.3%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = -1.8% (Analyst 2.9% - Implied 4.7%)
External Resources
Dataroma Stockcircle